Search
Search titles only
By:
Search titles only
By:
Log in
Register
Search
Search titles only
By:
Search titles only
By:
Menu
Install the app
Install
Forums
New posts
All threads
Latest threads
New posts
Trending threads
Trending
Search forums
What's new
New posts
New ads
New profile posts
Latest activity
Free Ads
Latest reviews
Search ads
Members
Current visitors
New profile posts
Search profile posts
Contact us
Latest ads
Pure VPN - Up to 27 Months
vgp
Updated:
Yesterday at 8:10 AM
එක පැකේජ් එකයි මාසෙටම Unlimited Internet. තාමත් DATA CARD දාන්න සල්ලි වියදම් කරනවද? අඩුම මිලට අපෙන්.
sayuru bandara
Updated:
Tuesday at 12:30 PM
Ad icon
ඉන්ටර්නෙට් එකෙන් හරියටම සල්ලි හොයන්න සහ Success වෙන්න කැමතිද? 🚀 (E-Money & Success Stories)
siri sumana
Updated:
May 30, 2026
Gemini AI PRO 18 months Offer
Hawaka
Updated:
May 27, 2026
Ad icon
koko account
DasunEranga
Updated:
May 27, 2026
Electronics
Vehicles
Property
Search
Reply to thread
Forums
ElaKiri.com
News and Updates
The Lambda Variant - Details
Get the App
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
<blockquote data-quote="imhotep" data-source="post: 26627448" data-attributes="member: 562115"><p>This variant was first identified in Lima, Peru in <strong>early November 2020</strong>, and has since spread to six other South American countries and 22 more in North America, the Caribbean, Europe, Israel in the Middle East, Zimbabwe, the UK and recently in Australia.</p><p></p><p>By the April and May of this year, this variant became dominant and accounted for <strong>four in every five cases in Peru,</strong> and a significant proportion in neighbouring Chile, Argentina, and Ecuador.</p><p></p><p>It's a sublineage<strong> within B.1.1.1 </strong>now classified as <strong>C.37</strong></p><p></p><p>Researchers at the Welcome Sanger Institute in the UK (Covid-19 Genomics) state that "Lambda has a unique pattern of seven mutations in the spike protein and they are particularly intrigued by one mutation called L452Q, which is similar to the L452R mutation to contribute to the high infectiousness of the Delta variant."</p><p></p><p>PHE (Public Health England) states that -</p><p>"There is currently no evidence that this variant causes more severe disease or renders the vaccines currently deployed any less effective"</p><p></p><p>A study published on last Monday found evidence that mRNA-type vaccines still effective and PHE probably backed that.</p><p></p><p>Also PHE mentions that this variant can present with -</p><p>A high temperature</p><p>A new, continuous cough</p><p>A loss or change to sense of smell or taste</p><p></p><p><strong>BUT,</strong> if you look at the data from Peru, it shows a mortality rate from the new variant of nearly 600 per 100,000 or <strong>six percent — twice as high </strong>as the roughly three percent seen in other countries. It's not clear whether the variant or the overwhelmed medical system accounted for more deaths.</p><p></p><p>For anyone interested here are the shared mutations and deletions of this variant.</p><p></p><table style='width: 100%'><tr><td>Gene</td><td>Amino acid</td></tr><tr><td>N</td><td>P13L, R203K, G204R, G214C</td></tr><tr><td>ORF1a</td><td>T1246I, P2287S, F2387V, L3201P, T3255I, G3278S, <strong>S3675-, G3676-, F3677-</strong>, K3678R</td></tr><tr><td>ORF1b</td><td>P314L</td></tr><tr><td>ORF9b</td><td>P10S</td></tr><tr><td>S</td><td>G75V, T76I, <strong>R246-, S247-, Y248-, L249-, T250-, P251-, G252-</strong>, L452Q, F490S, D614G, T859N</td></tr></table><p></p><p>Notes: </p><p>Deletions in the ORF1a and Spike genes are shown in<strong> bold</strong>.</p><p>This lineage also share a <strong>distinct</strong> <strong>seven-amino acid deletion</strong> in the Spike gene (S: Δ246-252).</p><p>There's a novel combination of nonsynonymous mutations in Spike: G75V, T76I, L452Q, F490S, T859N.</p><p>Mutations L452Q and F490S both map to the Spike protein’s receptor-binding domain (RBD). L452Q is almost exclusive to C.37.</p><p></p><p>S:Δ246-252 deletion should be taken into consideration for validation of diagnostic tests - as some kits might fail.</p></blockquote><p></p>
[QUOTE="imhotep, post: 26627448, member: 562115"] This variant was first identified in Lima, Peru in [B]early November 2020[/B], and has since spread to six other South American countries and 22 more in North America, the Caribbean, Europe, Israel in the Middle East, Zimbabwe, the UK and recently in Australia. By the April and May of this year, this variant became dominant and accounted for [B]four in every five cases in Peru,[/B] and a significant proportion in neighbouring Chile, Argentina, and Ecuador. It's a sublineage[B] within B.1.1.1 [/B]now classified as [B]C.37[/B] Researchers at the Welcome Sanger Institute in the UK (Covid-19 Genomics) state that "Lambda has a unique pattern of seven mutations in the spike protein and they are particularly intrigued by one mutation called L452Q, which is similar to the L452R mutation to contribute to the high infectiousness of the Delta variant." PHE (Public Health England) states that - "There is currently no evidence that this variant causes more severe disease or renders the vaccines currently deployed any less effective" A study published on last Monday found evidence that mRNA-type vaccines still effective and PHE probably backed that. Also PHE mentions that this variant can present with - A high temperature A new, continuous cough A loss or change to sense of smell or taste [B]BUT,[/B] if you look at the data from Peru, it shows a mortality rate from the new variant of nearly 600 per 100,000 or [B]six percent — twice as high [/B]as the roughly three percent seen in other countries. It's not clear whether the variant or the overwhelmed medical system accounted for more deaths. For anyone interested here are the shared mutations and deletions of this variant. [TABLE] [TR] [TD]Gene[/TD] [TD]Amino acid[/TD] [/TR] [TR] [TD]N[/TD] [TD]P13L, R203K, G204R, G214C[/TD] [/TR] [TR] [TD]ORF1a[/TD] [TD]T1246I, P2287S, F2387V, L3201P, T3255I, G3278S, [B]S3675-, G3676-, F3677-[/B], K3678R[/TD] [/TR] [TR] [TD]ORF1b[/TD] [TD]P314L[/TD] [/TR] [TR] [TD]ORF9b[/TD] [TD]P10S[/TD] [/TR] [TR] [TD]S[/TD] [TD]G75V, T76I, [B]R246-, S247-, Y248-, L249-, T250-, P251-, G252-[/B], L452Q, F490S, D614G, T859N[/TD] [/TR] [/TABLE] Notes: Deletions in the ORF1a and Spike genes are shown in[B] bold[/B]. This lineage also share a [B]distinct[/B] [B]seven-amino acid deletion[/B] in the Spike gene (S: Δ246-252). There's a novel combination of nonsynonymous mutations in Spike: G75V, T76I, L452Q, F490S, T859N. Mutations L452Q and F490S both map to the Spike protein’s receptor-binding domain (RBD). L452Q is almost exclusive to C.37. S:Δ246-252 deletion should be taken into consideration for validation of diagnostic tests - as some kits might fail. [/QUOTE]
Insert quotes…
Verification
Hathara warak wissa keeyada? (Hathara wadi karanna 20)
Post reply
Top
Bottom